HC Wainwright Increases Earnings Estimates for Innoviva

Innoviva, Inc. (NASDAQ:INVA) – Stock analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Innoviva in a report released on Monday, August 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn $2.30 per share for the year, up from their prior forecast of $2.20. HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.20 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2027 earnings at $0.62 EPS and FY2027 earnings at $2.37 EPS.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Innoviva from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Cantor Fitzgerald dropped their price target on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and set a $42.00 price objective on shares of Innoviva in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a research note on Wednesday, June 24th. Finally, Zacks Research cut Innoviva from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $34.75.

Innoviva Trading Up 0.3%

Shares of Innoviva stock opened at $20.75 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.18 and a current ratio of 16.01. The company has a market capitalization of $1.53 billion, a P/E ratio of 5.06 and a beta of 0.35. Innoviva has a 1 year low of $16.52 and a 1 year high of $25.15. The company’s fifty day moving average is $22.02 and its two-hundred day moving average is $22.32.

Hedge Funds Weigh In On Innoviva

A number of large investors have recently bought and sold shares of INVA. Parallel Advisors LLC lifted its stake in shares of Innoviva by 82.8% in the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 534 shares during the period. Allworth Financial LP acquired a new position in shares of Innoviva during the second quarter worth about $42,000. EverSource Wealth Advisors LLC increased its stake in shares of Innoviva by 297.7% during the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,795 shares during the period. Danske Bank A S acquired a new position in shares of Innoviva during the third quarter worth about $55,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Innoviva by 49.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 1,197 shares in the last quarter. Hedge funds and other institutional investors own 99.12% of the company’s stock.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin?out transaction in 2014, separating the royalty assets from a research?based biopharmaceutical enterprise to create a specialized investment vehicle.